Why should I join?

• You will receive some of your blood test results. We can also share these results with your healthcare provider.
• Your participation may improve the prevention of dementia for future generations.

Taking part in MAP is voluntary and will not affect the health care you receive.

You can withdraw from the study at any time.

To learn more about the MAP study, please contact our local study coordinator:

Hanson Research Team
(206) 744-1851 or (206) 897-5393
hansonlab@uw.edu

or visit us at:
cuimc.columbia.edu/mapstudy

Join us in our fight to help prevent dementia

MAP is a research study looking at whether metformin can help prevent memory decline for people with mild memory concerns.

Funded by the: National Institute on Aging (Grant #: R01AG062624)

MAP
Metformin in Alzheimer’s dementia Prevention

Approval Date: January 21, 2021
Principal Investigator: José Luchsinger, MD
Protocol Number: JHUSIRB00000013
What is MAP?
MAP is a research study looking at an existing drug used for diabetes prevention. The study is testing if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo.

Randomized means you have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine.

There will be no charge to you for the study drug or study visits.

What happens at study visits?
First, you will answer some questions about yourself and take a few tests to see if the study is right for you. We will do as much of this by phone as possible, for your convenience.

Tests will include:
• memory and thinking activities
• a physical exam and blood draw

If you join the study, you will:
• be randomized to get the study drug (metformin) or placebo
• take the study drug or placebo once a day for 2 years
• have an in-person visit once every 6 months, for a total of 5 visits
• answer questions about yourself and your medical history
• do memory and thinking activities
• have physical exams and blood draws
• have monthly calls between visits

About half of participants will also have brain imaging done at the beginning and end of the study. You are not required to have brain imaging done to be in the study.

You will be compensated for each study visit you complete.

Can I join?
You may be able to join the study if:
• you are 55-90 years old,
• you or your loved ones have noticed some changes in your memory, and
• you are not already being treated for diabetes or dementia

Randomized means you have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine.

MAP is a research study looking at an existing drug used for diabetes prevention. The study is testing if this drug can help prevent a decline in memory and thinking abilities for people with mild memory problems. It is a randomized study in which you will take either metformin (Glucophage® XR) or a placebo.

Randomized means you have an equal opportunity of getting the study drug or placebo. A placebo is a pill that looks the same as the study drug, but has no medicine.

There will be no charge to you for the study drug or study visits.